Drug profile · INN
osilodrostat phosphate
ISTURISA
osilodrostat phosphate (ISTURISA) is a cytochrome p450 11b1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — osilodrostat phosphate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
osilodrostat phosphate (ISTURISA) is a cytochrome p450 11b1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 11B1 inhibitor
Primary target: Cytochrome P450 11B1, mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is osilodrostat phosphate?
osilodrostat phosphate (ISTURISA) is a cytochrome p450 11b1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for osilodrostat phosphate?
ISTURISA is a marketed brand name for osilodrostat phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of osilodrostat phosphate?
osilodrostat phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.